Stoke Therapeutics (NASDAQ: STOK) counsel sells shares to cover tax withholding

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. General Counsel and Corporate Secretary Jonathan Allan reported open‑market sales of 8,895 shares of common stock in multiple transactions on March 17–18. A footnote states these sales were issuer‑mandated to satisfy tax withholding liabilities from vesting restricted stock units. After the transactions, he holds 28,836 shares of common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allan Jonathan

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GENERAL COUNSEL & CORP SEC

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		2,476	D	$32.7394(2)	35,255	D
Common Stock	03/17/2026		S(1)		1,791	D	$33.3754(3)	33,464	D
Common Stock	03/18/2026		S(1)		4,222	D	$31.2838(4)	29,242	D
Common Stock	03/18/2026		S(1)		334	D	$31.7888(5)	28,908	D
Common Stock	03/18/2026		S(1)		72	D	$32.85	28,836	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive.

5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive.

	/s/ Jonathan Allan	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Stoke Therapeutics (STOK) report on this Form 4?

Stoke Therapeutics reported that General Counsel Jonathan Allan sold 8,895 shares of common stock. The sales occurred in several open‑market transactions on March 17–18 and were linked to recently vested restricted stock units and related tax obligations.

Why did Jonathan Allan sell Stoke Therapeutics (STOK) shares in this filing?

The filing states the sales were issuer‑mandated to cover tax withholding liabilities from the vesting and settlement of restricted stock units. This means the transactions were primarily to meet tax obligations rather than a discretionary decision to reduce his investment exposure.

How many Stoke Therapeutics (STOK) shares did the insider sell and at what prices?

Jonathan Allan sold a total of 8,895 shares of common stock. The weighted average prices disclosed for the various trades range roughly from about $30.59 to $33.855 per share, with detailed price breakdowns available upon request from the company or regulators.

How many Stoke Therapeutics (STOK) shares does Jonathan Allan hold after these transactions?

After the reported sales, Jonathan Allan directly owns 28,836 shares of Stoke Therapeutics common stock. This post‑transaction balance, shown in the Form 4 tables, reflects his remaining direct equity position following the tax‑related share dispositions.

Were Jonathan Allan’s Stoke Therapeutics (STOK) sales made under a trading plan?

The disclosure notes that the sales were mandated by the issuer to satisfy tax withholding on vested restricted stock units. The provided footnotes do not mention a Rule 10b5‑1 trading plan, focusing instead on the tax‑driven nature of the transactions.